Revenue segments as reported by the company.

Diabetes

Oncology

Immunology

Neuroscience

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Marketing, selling and administrative

Acquired in-process research and development

Asset impairment, restructuring and other special charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Eli Lilly

Cialis, ia a competitor to Pfizer's blockbuster Viagra for erectile dysfunction. Cialis maintains an active period of 36 hours.

Cialis

Cymbalta is a serotonin-norepinephrine reuptake inhibitor used predominantly in the treatment of major depressive disorders and generalized anxiety disorder, ranks with Prozac as one of the most financially successful pharmaceuticals in industry history. It is also used in the treatment of fibromyalgia, neuropathy, chronic pain and osteoarthritis.

Cymbalta

Gemzar is a treatment of pancreatic cancer. Gemzar is commonly used in the treatment of pancreatic cancer, usually in coordination with 5-FU chemotherapy and radiology. Gemzar also is routinely used in the treatment of non-small cell lung cancer.

Gemzar

Methadone is an analgesic used frequently in the treatment of heroin, opium and other opioid and narcotic drug addictions.

Methadone

Prozac was one of the first therapies in its class to treat clinical depression by blocking the uptake of serotonin within the human brain. It is prescribed to more than fifty-four million people worldwide.

Prozac

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Eli Lilly reports robust Q4 earnings, eyes growth in innovative therapies

Eli Lilly's Q4 2022 earnings call highlighted strong financial performance, pipeline advancements, and strategic initiatives for future growth.
The company's focus on innovation, FDA approvals, and market expansion underscores its commitment to addressing unmet medical needs and driving shareholder value.
Challenges in physician education, obesity treatment development, and market access present areas for strategic focus and investment for sustained growth.
Opportunities in expanding manufacturing capacity, engaging with payers, and capitalizing on consumer interest in obesity treatments position Lilly for continued success in 2023.

Eli Lilly reports robust Q1 growth amidst capacity challenges

Eli Lilly's Q1 2023 performance reflects strong revenue growth and strategic investments in new products and facilities.
While facing challenges in capacity and supply pressure, the company's focus on pipeline advancements and market opportunities positions it for future growth.
Opportunities in international markets, cardiovascular trials, and product promotion present avenues for continued expansion and revenue growth.
Overall, Eli Lilly's financial performance, product strengths, and strategic initiatives demonstrate a resilient and growth-focused approach.

Eli Lilly reports robust Q2 earnings, eyes growth through innovation

Eli Lilly's Q2 earnings call showcased strong financial performance, revenue growth, and advancements in its pipeline, driven by key products and strategic investments.
The company faces challenges in managing increased expenses, supply chain constraints, and regulatory considerations, requiring strategic decision-making and operational agility.
Opportunities lie in expanding market access, leveraging innovative treatments like tirzepatide, and enhancing manufacturing capabilities to drive future growth and competitive advantage.
Overall, Lilly's focus on innovation, market expansion, and addressing health needs positions it well for sustained growth and leadership in the pharmaceutical industry.

Eli Lilly posts robust Q3 results, eyes expansion and commercial growth

Eli Lilly (LLY) showcased strong financial performance and pipeline advancements in Q3 2023.
Challenges include supply restrictions and pricing decisions, but opportunities lie in expansion plans and commercial coverage ramp-up.
Investors advised to focus on guidance range for insights into 2024 expectations.

Eli Lilly posts robust Q4 results, eyes global expansion opportunities

Eli Lilly's strong financial performance in Q4 2023, driven by revenue growth and operational efficiency, sets a solid foundation for future growth.
The company's strategic acquisitions, global expansion plans, and focus on innovation position it well for continued success and market leadership.
Challenges in drug development and manufacturing require careful navigation, but opportunities in new drug trials and market expansion offer avenues for growth.
Overall, Eli Lilly's 2023 was marked by productivity and anticipation of sustained momentum in 2024, reflecting a positive outlook for the company.

Eli Lilly reports robust Q1 growth, eyes pipeline opportunities

Eli Lilly's Q1 performance showcased strong revenue growth, driven by new products and global market expansion.
While facing challenges like low Zepbound volume and manufacturing complexities, Lilly's strengths in innovation and market presence position it well for growth.
Opportunities in pipeline advancements, differentiation in drug portfolios, and potential Alzheimer's treatments signal a promising future for the company.
Overall, Eli Lilly's strategic focus on growth, innovation, and market expansion sets a positive trajectory for continued success.

Eli Lilly reports stellar Q3 results, eyes global expansion opportunities

Eli Lilly's Q3 performance reflects robust revenue growth, driven by new products and strategic investments, positioning the company for continued success.
Key pipeline advancements and revenue guidance raise optimism for future growth, with a focus on global scaling and market expansion initiatives.
Challenges in patient adherence and treatment efficacy are being addressed, while opportunities in market penetration and revenue growth are actively pursued.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Lilly (LLY) delivered earnings and revenue surprises of -12.50% and -2.36%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Eli Lilly (LLY) Q3 Earnings and Revenues Miss Estimates

LY-CoV555, which was being tested in combination with Gilead Sciences' remdesivir, showed no evidence of benefiting hospitalized COVID-19 patients.

NIH Ends Clinical Trial of Eli Lily's Coronavirus Antibody Therapy Candidate

"It's disappointing, of course. We would have liked to have shown a benefit in the hospital," Eli Lilly CEO Dave Ricks told CNBC.

Eli Lilly still confident in benefits of Covid antibody treatment despite end to hospital study

Gilead Sciences

The feds have stopped a clinical trial of two coronavirus treatments after determining the combination of drugs wasn't helping hospitalized patients. The study aimed to evaluate whether Eli Lilly and Co.'s antibody treatment was effective in people hospitalized for COVID-19 who were also receiving remdesivir, the antiviral drug developed by Gilead Sciences.

Feds end study trying to treat COVID-19 with Eli Lilly antibody, remdesivir

Eli Lilly early Tuesday posted third-quarter earnings and sales that missed Wall Street expectations and said that one of its Covid-19 treatments failed in clinical trials; LLY stock fell. The post LLY Stock Falls As Eli Lilly Earnings Miss, Covid-19 Treatment Fails In Trials appeared first on Investor's Business Daily.

LLY Stock Falls As Eli Lilly Earnings Miss, Covid-19 Treatment Fails In Trials

Eli Lilly & Co. shares fell 4% in premarket trade Tuesday, after the drug maker posted weaker-than-expected earnings for the third quarter. Indianapolis-based Eli Lilly said it had net income of $1.208 billion, or $1.33 a share, in the quarter, down from $1.254 billion, or $1.37 a share, in the year-earlier period.

Eli Lilly shares slump premarket after earnings miss

Eli Lilly and Co reported a 4% fall in the third-quarter profit on Tuesday due to higher costs.

Eli Lilly third-quarter profit slips 4%

INDIANAPOLIS, Oct. 27, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced financial results for the third quarter of 2020. $ in millions, except per share data Third Quarter % 2020 2019 Change Revenue $ 5,740.6 $ 5,476.6 5% Net Income – Reported 1,208.4 1,253.9 (4)%...

Lilly Reports Third-Quarter Financial Results, Updates Guidance

Eli Lilly and Company (NYSE: LLY) said Monday that a trial of its antibody treatment for use in hospitalized COVID-19 patients has come to an end as the treatment is unlikely to help such patients.  What Happened: The one of its kind study — conducted by the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health — was evaluating the efficacy of bamlanivimab, according to a statement issued by the company.

NIAID Study Finds Eli Lilly's Antibody Drug Unhelpful For Hospitalized COVID-19 Patients

Eli Lilly said it is 'confident' the therapy might prevent progression for people in earlier stages of the virus.

Eli Lilly Ends Covid-19 Antibody Trial After Finding It's Unlikely To Help Hospitalized Patients

Our extensive research has shown that imitating the smart money can generate significant returns for retail investors, which is why we track nearly 823 active prominent money managers and analyze their quarterly 13F filings. The stocks that are heavily bought by hedge funds historically outperformed the market, though there is no shortage of high profile failures like hedge funds' 2018 losses in Facebook and Apple. Let's take a closer look at what the funds we track think about Eli Lilly and Company (NYSE:LLY) in this article.

Were Hedge Funds Right About Eli Lilly and Company (LLY)?

Eli Lilly had paused its Covid-19 study using bamlanivimab and remdesivir treating hospitalized patients. There are still 3 other ongoing studies in earlier stage Covid-19 patients that have not been paused. The company acquired Disarm Therapeutics for an upfront payment of $135 million. Disarm shareholders are eligible to earn up to $1.25 billion in milestone payments.

Eli Lilly Pauses COVID-19 Study; Latest Acquisition Provides Potential To Target Large Markets

NEW YORK, Oct. 22, 2020 /PRNewswire/ -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors who purchased shares of Eli Lilly and Company ("Eli Lilly" or the "Company") (NYSE: LLY). On October 13, 2020, the Company announced that it was pausing...

Investor Alert: Kaplan Fox Investigates Eli Lilly For Potential Securities Fraud

Los Angeles, California--(Newsfile Corp. - October 21, 2020) -  The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Eli Lilly and Company ("Eli Lilly" or "the Company") (NYSE: LLY) for violations of the securities laws.The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. On October 13, 2020, the National Institute of Allergy...

ONGOING INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Eli Lilly and Company and Encourages Investors with Losses of $100,000 to Contact the Firm

Higher demand for its growth drugs is likely to have offset generic competition for several other drugs to boost Lilly's (LLY) third-quarter sales.

Will Lilly (LLY) Witness Recovery in Sales in Q3 Earnings?

Eli Lilly and Co said late on Tuesday it had hired an independent consultant to review a plant producing its promising COVID-19 drug after receiving notices from the U.S. health regulator.

Lilly hires outside advisor for COVID drug plant problems

NEW YORK, Oct. 20, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eli Lilly and Company ("Eli Lilly" or the "Company") (NYSE: LLY). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980. The...

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eli Lilly and Company - LLY

In the latest trading session, Eli Lilly (LLY) closed at $143.59, marking a +0.55% move from the previous day.

Eli Lilly (LLY) Outpaces Stock Market Gains: What You Should Know

LOS ANGELES--(BUSINESS WIRE)---- $LLY #classaction--The Law Offices of Frank R. Cruz continues its investigation of Eli Lilly and Company (“Eli Lilly” or the “Company”) (NYSE: LLY) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. In August 2020, the Company began a clinical trial to test whether adding the Company's antibody-based drug, LY-CoV555, to remdesivir would benefit patients diagnosed with

The Law Offices of Frank R. Cruz Continues Its Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

BENSALEM, Pa.--(BUSINESS WIRE)---- $LLY #CLASSACTION--INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

Regeneron Pharmaceuticals

How Monoclonal Antibodies Can Treat COVID-19 and What the Data Says About Vaccines

New York, New York--(Newsfile Corp. - October 19, 2020) -  Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Eli Lilly and Company ("Eli Lilly" or the "Company") (NYSE: LLY).If you suffered losses exceeding $100,000 investing in Eli Lilly stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/LLY. There is no cost or obligation to you.

Eli Lilly Investor Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Eli Lilly and Company To Contact The Firm

LOS ANGELES--(BUSINESS WIRE)---- $LLY #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of Eli Lilly and Company (LLY) on Behalf of Investors

Moderna

How Should Investors Play COVID-19 Stocks?

INDIANAPOLIS, Oct. 19, 2020 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the fourth quarter of 2020 of $0.74 per share on outstanding common stock. The dividend is payable December 10, 2020, to shareholders of record at the close...

News for Eli Lilly Stock (LLY)